Show simple item record

dc.contributor.authorDizer, Ufuk
dc.contributor.authorGörenek, Levent
dc.contributor.authorGüner, Ozgür
dc.contributor.authorPehlivan, Tamer
dc.contributor.authorOzgüven, Volkan
dc.contributor.authorPahsa, Alaaddin
dc.description.abstractTyphoid fever is a disease predominant in underdeveloped and developing countries. Typhoid fever is more prevalent, in fact endemic, in countries where fecal contamination of water and food sources are very common. The majority of the reported cases are in the adult age group. There are three different vaccines which can be used to prevent typhoid fever. In this study, we have used the parenteral Vi vaccine which was developed using the polysaccharide Vi antigen that covers the bacterial surface, thus, concealing the O antigen protecting the bacteria against Anti-O antibodies and regarded as virulence factor. A total of 110 individuals whose sera were negative for seroconversion prior to vaccination were included in this study in which we have assessed Anti-Vi antibodies by tube agglutination. Serum and stool samples of 110 individuals were assessed 1 month after the vaccination. A total of 105 (95.5%) of the vaccinated people were considered to have positive (1/40 and higher) response and this result was regarded as prophylactic seroconversion. None of the people in the study group had Salmonella typhi, S. paratyphi A,B,C isolated from their stool cultures.en_US
dc.publisherSağlık Bilimleri Enstitüsüen_US
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 United States*
dc.titleAssessment of the antibody response in 110 healthy individuals who have been subject to Vi capsular polysaccharide vaccine.en_US
dc.contributor.departmentDahili Tıp Bilimlerien_US

Files in this item


This item appears in the following Collection(s)

Show simple item record

Except where otherwise noted, this item's license is described as info:eu-repo/semantics/openAccess